Brad Sitko

Brad Sitko has worked in a variety of roles in the finance and healthcare industries since 2003. Theirmost recent position is Chief Investment Officer at XOMA, a role they have held since 2023. Prior to this, they were a Director (Board Member) at RTW Investments ICAV from 2021 to 2023, Managing Director, Strategic Finance at RTW Investments, LP from 2019 to 2021, Chief Financial Officer at Jixing Pharmaceuticals from 2019 to 2021, Vice President, Finance, Operations & Corporate Development (Acting CFO/COO) at DNAnexus from 2015 to 2019, Director, Healthcare Investment Banking at MTS Health Partners from 2008 to 2015, Associate - WW Strategic Planning & Innovation and Associate - Business Development - Portfolio & Decision Analysis (PDA) at Pfizer from 2008 to 2015, Consultant at The Frankel Group / BioDevelopment Ventures from 2005 to 2008, Analyst - Healthcare Consulting & Strategic Insight at Datamonitor from 2003 to 2005, and Director of Sales & Marketing at Lobeman Group from 2003 to 2005.

Brad Sitko's education history includes attending Midpark High School from 1994 to 1998, the University of Pennsylvania from 1998 to 2002, where they earned a BA in History and Sociology of Science (Bioethics), and Columbia Business School from 2007 to 2009, where they earned an MBA in Finance, Healthcare and Pharmaceutical Management.